Leap Therapeutics secures $58.9M PIPE to launch digital asset strategy; shares up 29%

* Leap Therapeutics (NASDAQ:LPTX [https://seekingalpha.com/symbol/LPTX]) announced a $58.9M PIPE financing led by Winklevoss Capital to support a new digital asset treasury strategy.
* The offering includes ~95.8M shares (or pre-funded warrants) and ~71.9M warrants exercisable at $0.5335 per share, priced at $0.61439 per unit.
* Proceeds will support both Leap’s digital asset initiatives and its oncology programs, including FL-501 and sirexatamab.
* Sirexatamab recently completed a Phase 2 colorectal cancer trial, to be presented at ESMO Congress 2025 on October 19 in Berlin.
* Winklevoss Capital gains board influence with the right to nominate two directors, including the board chairperson.
* The private placement is expected to close on or about October 8, 2025.
* LPTX shares up 29% on Monday.
* Source: Press release [https://seekingalpha.com/pr/20255530-leap-therapeutics-announces-58_88-million-private-placement-in-cash-commitments-led-by]

MORE ON LEAP THERAPEUTICS

* Seeking Alpha’s Quant Rating on Leap Therapeutics [https://seekingalpha.com/symbol/LPTX/ratings/quant-ratings]
* Historical earnings data for Leap Therapeutics [https://seekingalpha.com/symbol/LPTX/earnings]
* Financial information for Leap Therapeutics [https://seekingalpha.com/symbol/LPTX/income-statement]